Nesfatin-1 is an 82 amino acid protein encoded by the nucleobindin2 gene. When injected intracerebroventricularly, nesfatin-1, via a melanocortin ¾ receptor-dependent mechanism, potently decreased both food and water intakes and elevated mean arterial pressure in a dose-related manner. Because nesfatin-1 colocalized with oxytocin in hypothalamus, and because nesfatin-1 had direct depolarizing effects on oxytocin producing neurons in hypothalamic slice preparations, we hypothesized that the actions of nesfatin-1 required the presence of functional oxytocin receptors. We therefore pretreated conscious, unrestrained male rats with the oxytocin receptor antagonist, OVT, before treatment with nesfatin-1. We found that pretreatment with OVT reversed the effects of nesfatin-1 on both food and water intake and on mean arterial pressure, indicating that the central oxytocin system is a downstream mediator of these actions of nesfatin-1. Additionally, we found that OVT reversed the anorexigenic effect of alpha-MSH, suggesting that the central oxytocin system is downstream of the central melanocortin system. Taken together, these data suggest that nesfatin-1 acts through serial neuronal circuit, in which nesfatin-1 activates the central melanocortin system, which in turn acts through the central oxytocin system, leading to an inhibition of food and water intake and an increase in mean arterial pressure.
Introduction
Nesfatin-1 is a recently discovered, 82 amino acid protein derived from the nucleobindin2 (NUCB2) precursor (Oh-I et al., 2006) . Nesfatin-1 is produced in several hypothalamic nuclei, such as the paraventricular nucleus (PVN), supraoptic nucleus (SON), arcuate nucleus, and lateral hypothalamic area (LHA) (Oh-I et al., 2006) , and in extra-hypothalamic areas as well, including the raphe pallidus, the Edinger-Westphal nucleus, and the nucleus of the solitary tract (NTS) (Foo et al., 2008) . Although nesfatin-1 has been shown to colocalize with several well-described peptides, including cocaine and amphetamine-regulated transcript (CART), corticotropin releasing factor (CRF), oxytocin, and vasopressin, nesfatin-1 has not been visualized in axons terminals (Foo et al, 2008 ). This has led several groups (Foo et al., 2008; Stengel et al., 2009; Yosten and Samson, 2009 ) to speculate that nesfatin-1 does not signal via a classical axonal mechanism, but rather is released dendritically to act locally in a paracrine or autocrine fashion.
Nesfatin-1 originally was shown to be a potent inhibitor of both food and water intake via a leptin-independent, melanocortin receptor-dependent mechanism (Oh-I et al., 2006 ; Yosten and Samson, 2009 ). Nesfatin-1 is likely a physiologically relevant regulator of food intake, as chronic central administration of a morpholino antisense oligonucleotide led to exaggerated food intake and weight gain over missense-injected controls (Oh-I et al., 2006) . Additionally, plasma levels of nesfatin-1 were significantly reduced by fasting, and this effect was reversed by refeeding (Stengel et al., 2009) . We recently have shown that nesfatin-1 increases mean arterial pressure (MAP) when injected into the lateral cerebroventricle (i.c.v.) (Yosten and Samson, 2009 ). This effect, like the effect of nesfatin-1 on food intake, was blocked by pretreatment with the melanocortin ¾ receptor antagonist, SHU9119 (Yosten and Samson, 2009 ). The increase in MAP induced by nesfatin-1 also was blocked by pretreatment with the non-specific alpha-adrenergic antagonist, phentolamine, suggesting that nesfatin-1 acts through the central melanocortin system to increase sympathetic nervous system activity, leading to an elevation in MAP (Yosten and Samson, 2009 ). In addition to the central melanocortin system, it appears that a forebrain site of action involving the recruitment of CRF neurons underlies the anorexigenic action of nesfatin-1, when administered into the lateral, but not the fourth, cerebroventricle (Stengel et al., 2009) . It is unknown, however, what other neuronal populations may be involved in the expression of the anorexigenic and hypertensive effects of nesfatin-1.
Oxytocin was originally described based on its effects on uterine contractility and mammary tissue (den Hertog et al., 2001; Du Vigneaud et al., 1954) . The central oxytocin system, which is comprised of both magnocellular (projecting to posterior pituitary and locally acting via dendritic release) and parvocellular (projecting to brainstem and other brain sites) oxytocin-producing neurons, is important for the expression of maternal, sexual, and feeding behaviors, and the control of cardiovascular function as well (Sabatier et al., 2003b; Michelini et al., 2003) . Because nesfatin-1 colocalized with oxytocin in neurons in the PVN (Foo et al., 2008) , and because nesfatin-1 had direct depolarizing effects on oxytocin neurons in hypothalamic slice preparations (Price et al., 2008) , we hypothesized that the central oxytocin system was a downstream mediator of the anorexigenic, antidipsogenic, and hypertensive activities of nesfatin-1.
Indeed, a recent report (Maejima et al., 2009 ) demonstrated that the inhibitory effect of nesfatin-1 on food intake was dependent on central oxytocin receptors. Here we confirm the findings of Maejima et al. on food intake, and add that the effects of nesfatin-1 on water intake and on MAP could be blocked by pretreatment with the oxytocin receptor antagonist, ornithine vasotocin (OVT). We also add that the anorexigenic action of alpha-melanocyte stimulating hormone (alpha-MSH) was reversed by pretreatment with OVT, suggesting that nesfatin-1 acts through a serial neuronal circuit, in which nesfatin-1 activates the central melanocortin system, which in turn acts through the central oxytocin system to increase mean arterial pressure and inhibit food and water intake.
Materials and Methods
All procedures and protocols have been approved by the Saint Louis University Animal Use and Care Committee (protocol number 2041). Adult male Sprague-Dawley rats (Harlan, Indianapolis, IN) were housed under controlled conditions (23-25°C, lights on 0600-1800hr) with free access to food and water. Rats (225-250g; approximately 7-8 weeks of age) were anesthetized with a mixture of ketamine (60mg/ml; Ketaset, Fort Dodge Animal Health, Fort Dodge, IA) and xylazine (8mg/ml; TranquiVed, VedCo, Saint Joseph, MO) at a dose of 0.1 ml per 100 g body weight, injected intra-peritoneally, as previously described (Yosten and Samson, 2009 ). Buprenorphine (0.05 mg/kg body weight, injected subcutaneously) was administered post-anesthesia for analgesia. Fluid replacement included a subcutaneous injection of sterile saline (0.9% NaCl) to balance anticipated fluid loss (3:1). A stainless steel cannula (23 mm, 17 gauge) was implanted into the right lateral cerebroventricle (i.c.v.) using a stereotaxic device (coordinates relative to the interaural line: A: +6.2, L:+7.4, H:-0.9) and immobilized using dental cement. Rats were then housed singly and observed for at least 4 days following surgery to ensure recovery of pre-surgery weight. Placement and patency of the i.c.v. cannula was confirmed by the dipsogenic effect of angiotensin II (50 picomoles i.c.v.).
For feeding studies, rats bearing an i.c.v. cannula were habituated to metabolic cages (Nalgene) for 3 days. Food and water intakes and body weights were monitored daily to ensure health. On the day of the experiment, food and water were removed from the cages at 1650, and rats were pretreated i.c.v. with 2 microliters saline vehicle or 10 ug For cardiovascular experiments, an additional cannula (PE-50) was implanted into the left carotid artery of rats minimally five days after implantation of the i.c.v. cannulae, and exteriorized between the shoulder blades as previously described (Yosten and Samson, 2009 ). The cannula was filled with heparinized saline (200 U/ml in 0.9% NaCl). The next day (during lights on, between 0600 and 1800), rats were placed in a quiet room, and after minimally two hours habituation the carotid cannula was connected to a pressure transducer (DigiMed Blood Pressure Analyzer, Micro-Med, Louisville, KY). Baseline MAP and heart rate (HR) then were recorded at 1 minute intervals for at least 30 minutes. Rats were pretreated with either 2 microliters saline vehicle or vehicle containing 10 ug OVT (i.c.v.). Ten minutes later, rats were treated with either saline vehicle or 180 pmole nesfatin-1 (i.c.v.) and MAP and HR were recorded for at least 15 minutes at 1 minute intervals. Data are represented as change from pre-injection baseline, which was determined by averaging the MAP or HR values for 5 minutes before injection of nesfatin-1 or saline vehicle.
To determine plasma oxytocin levels, rats that were habituated to a quiet room were injected i.c.v. with either saline vehicle or 180 pmole nesfatin-1. 10 minutes later, rats were sacrificed by rapid decapitation and trunk bloods were collected. Plasma oxytocin levels were determined by radioimmunoassay as previously described (Samson et al., 2004) . The lower limit of sensitivity was defined as minimally 95% of total binding (2 pg/ml plasma).
Feeding data were analyzed using ANOVA with Scheffe's multiple comparison.
Cardiovascular data were analyzed using a non-parametric test (Mann-Whitney U), as MAP/HR data were transformed to represent change from pre-injection baseline because of the natural variation of resting MAP/HR between animals. Radioimmunoassay data were analyzed using a t test. All peptides were purchased from Phoenix Pharmaceuticals (Burlingame, CA). 60 pmole and 180 pmole nesfatin-1 were used for feeding experiments and cardiovascular experiments, respectively, because these were the most effective doses in each experimental paradigm (Yosten and Samson, 2009 ). The dose of OVT used in this study was determined based on the dose previously reported in the literature (Arletti et al., 1989) .
Results
Oxytocin inhibited both food and water intake when injected into the lateral cerebroventricle ( Figure 1A/B ). Although food intake was decreased at all time points compared to saline-injected controls, this effect was most clear during later time points, when the effect attained significance. The effect of oxytocin on water intake was less robust than the effect on food intake, but did attain significance during the last 3 time food intake compared to controls at 1730) ( Figure 2A ). Pretreatment with OVT reversed the inhibitory action of nesfatin-1, but did not affect food or water intake when injected alone. This reversal attained significance at the 30 and 60 minute sampling intervals.
Cumulative food intakes in animals administered nesfatin-1 after OVT at no time point differed significantly from intakes observed in saline vehicle controls or animals administered OVT and saline. When the data were analyzed by ANOVA, no significant differences in cumulative food intakes among treatment groups were observed at any subsequent (following 1900) sampling intervals (data not shown).
Central administration of 60 pmole nesfatin-1 significantly inhibited cumulative water intake as previously reported (Yosten and Samson, 2009 ). This decrease attained significance at the first three sampling periods when compared to cumulative water intakes in animals administered saline vehicle alone or the oxytocin antagonist and saline (nesfatin-1 induced an approximately 82% decrease in water intake compared to controls at 1730) ( Figure 2B ) and in the fourth interval (1900 hr) compared to water consumed in OVT and saline treated animals. Cumulative water intakes in animals administered nesfatin-1 after OVT at no time point differed significantly from intakes observed in saline vehicle controls or animals administered OVT and saline. However, a significant reversal of the inhibitory effect of nesfatin-1 on water drinking was observed following OVT pretreatment at 90 minutes. While more water was consumed by animals treated with OVT and nesfatin-1 compared to those treated with saline and nesfatin-1 at all sampling times, this attained significance only at the 90 minute sampling interval.
Increased water consumption was observed in the nesfatin-1 treated animals following the fourth sampling interval (after 1900 hr) such that no significant differences in cumulative water consumption were observed compared to controls thereafter (data not shown).
Because the anorexigenic and antidipsogenic effects of nesfatin-1 were completely reversed by pretreatment with a melanocortin ¾ receptor antagonist (Oh-I et al., 2006; Yosten and Samson, 2009 ) and an oxytocin receptor antagonist (Figure 2A Animals that received saline and alpha-MSH consumed significantly less food and water than animals that were injected with saline alone (Figure 3A/B) . However, the effect of alpha-MSH on food intake was reversed by pretreatment with OVT. OVT also reversed the effect of alpha-MSH on water intake, although this effect did not attain significance until 1900 hours.
Because nesfatin-1 acts through the central melanocortin system to affect both food and water intake and MAP (Oh-I et al., 2006; Yosten and Samson, 2009), we sought to determine if the central oxytocin system was a point of convergence or divergence for the different effects of the protein (i.e. appetitive versus autonomic). We therefore tested the ability of OVT to block the hypertensive action of nesfatin-1.
In conscious, freely moving rats, 180 pmole nesfatin-1 led to significant increases in MAP ( Figure 4A ), as previously reported (Yosten and Samson, 2009 ). Pretreatment with 10 ug OVT did not affect resting MAP (Table 1) , nor did OVT/saline-treated rats exhibit any alterations from pre-injection baseline. However, pre-treatment with OVT completely abolished the stimulatory effect of nesfatin-1 on MAP. No significant increases in HR were observed in any of the treatment groups ( Figure 4B 
Discussion
Oxytocin has been shown to act in brain to inhibit food intake (Olson et al., 1991) and alter cardiovascular function (Michelini et In these studies, we found that the actions of nesfatin-1 on food and water intake and MAP could be blocked by pretreatment with the oxytocin receptor antagonist, OVT, suggesting that functional oxytocin receptors are required to mediate the actions of nesfatin-1. Although it has been reported previously (Fitts et al., 2003 ) that OVT alone led to an exaggeration of water intake, this effect was not observed in our experiments. This is likely due to strain differences, as the studies by Fitts and colleagues utilized Long-Evans rats, while all of our experiments are conducted using Sprague-Dawley rats.
In our experiments, OVT did not alter food intake. This is in accordance with previous a report (Blevins et al., 2004) which demonstrated that OVT does not lead to exaggerated food intake unless injected into the fourth ventricle (our injections are made into the lateral ventricle). We previously have reported that the activities of nesfatin-1 also require the presence of functional melanocortin receptors (Yosten and Samson, 2009) .
While it is possible that the central melanocortin system and the central oxytocin system operate in parallel to simultaneously exert the effects of nesfatin-1, these two neuronal circuits may also act in series. Melanocortin agonists and oxytocin exerted similar actions on a variety of physiological functions when injected into brain, including the initiation of the yawning-stretching reflex and sexual behaviors (Sabatier et al., 2003b) . peptide that is dependent on the central melanocortin system to exert its activities (Dunbar and Lu, 1999) . Here we also show that the anorexigenic effect of alpha-MSH is reversed by pretreatment with OVT (see Figure 3 ). Additionally, alpha-MSH was shown to increase the dendritic release of oxytocin in hypothalamus, but to inhibit the release of oxytocin from axon terminals in the posterior pituitary gland leading to a decrease in plasma OT levels (Sabatier et al., 2003a) . Nesfatin-1 may indeed increase dendritic release of oxytocin, as a recent report (Maejima et al., 2009 ) indicated that nesfatin-1 led to an increase in oxytocin secretion within the PVN and evidence from our laboratory indicates that nesfatin-1 does not affect basal plasma levels of oxytocin in conscious male rats. In our experiments, we did not observe a decrease in plasma oxytocin levels, unlike the decrease in oxytocin reported by Sabatier and colleagues (2003a) after treatment with melanocortin agonists. The difference is likely due to differences in model systems. Rats bearing i.c.v. and carotid cannulae were pretreated with 10 ug OVT or saline vehicle i.c.v. 10 minutes later, rats were treated with either saline vehicle or 180 pmole nesfatin-1 (Time 0). While nesfatin-1 led to significant increases in MAP (panel a), this effect was blocked by pretreatment with OVT. None of the treatment groups exhibited any significant increases in HR (panel b). Data are represented as change from preinjection baseline (average 5 minutes before i.c.v. injection). Data were analyzed using a Mann-Whitney U test (*p<0.05, **p<0.01, ***p<0.001, versus saline-injected controls). Table 1 : Neither OVT nor saline pretreatment altered baseline MAP. Data are presented as average MAP for 5 minutes before or after pretreatment with either 10 ug OVT or saline vehicle i.c.v.
